CG Oncology's bladder cancer treatment beats expectations in Phase 3
CG Oncology said its oncolytic immunotherapy succeeded in a late-stage trial in certain patients with non-muscle invasive bladder cancer, potentially expanding the asset’s market significantly. Cretostimogene grenadenorepvec met the Phase 3 ...
comments(0)
5-min edit window · permanent after that